Download PDF
Horm Metab Res
DOI: 10.1055/a-2272-5165
Original Article: Endocrine Care

Correlation Between TRAb and Early Onset Hypothyroidism After 131I Treatment for Gravesʼ Disease

Qi Song‡
1   Endocrine Department, Second Affiliated Hospital of Soochow University, Suzhou, China
,
Zhouyu Fang‡
1   Endocrine Department, Second Affiliated Hospital of Soochow University, Suzhou, China
,
Shurong Wang
1   Endocrine Department, Second Affiliated Hospital of Soochow University, Suzhou, China
,
Zhihua Liu
1   Endocrine Department, Second Affiliated Hospital of Soochow University, Suzhou, China
,
Wenjin Xiao
1   Endocrine Department, Second Affiliated Hospital of Soochow University, Suzhou, China
,
Haijun Zong 
1   Endocrine Department, Second Affiliated Hospital of Soochow University, Suzhou, China
,
Ying Xie 
1   Endocrine Department, Second Affiliated Hospital of Soochow University, Suzhou, China
› Author Affiliations Funding Information The State Key Laboratory of Radiation Medicine and Radiation Protection Open Project (2023) — GZK12023033 Suzhou Science and Technology Planning Project — SKJY2021082
› Further Information
Also available at
    Permissions and Reprints

Abstract

The aim of the study was to explore the clinical features related to early hypothyroidism and the relationship between the changes of thyrotropin receptor antibodies (TRAb) and early hypothyroidism in the course of 131I treatment for Graves’ disease. This study was a retrospective observation, including 226 patients who received the first 131I treatment. The general information and laboratory tests were collected before and after 131I treatment, and the laboratory data affecting the difference in disease outcome were analyzed. According to the changes of antibodies in the third month, whether the changes of antibodies were involved in the occurrence of early-onset hypothyroidism was analyzed. Early onset hypothyroidism occurred in 165 of 226 patients, and the results showed that the incidence of early hypothyroidism was higher in patients with low baseline TRAb level (p=0.03) and increased TRAb after treatment (p=0.007). Both baseline TRAb levels (p<0.001) and the 24-hour iodine uptake rate (p=0.004) are significant factors influencing the changes in TRAb. The likelihood of a rise in TRAb was higher when the baseline TRAb was less than 18.55 U/l and the 24-hour iodine uptake level exceeded 63.61%. Low baseline and elevated post-treatment levels of TRAb were significantly associated with early-onset hypothyroidism after 131I treatment. Monitoring this index during RAI treatment is helpful in identifying early-onset hypothyroidism and mastering the clinical outcome and prognosis of Graves’ disease.

Keywords

early onset hypothyroidism - 131I treatment - thyrotropin receptor antibody - Gravesʼ disease - retrospective observation


Publication History

Received: 29 November 2023

Accepted after revision: 15 February 2024

Article published online:
04 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lantz M, Planck T, Asman P. et al. Increased TRAb and/or low anti-TPO titers at diagnosis of Graves' disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 2014; 122: 113-117
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Hargreaves CE, Grasso M, Hampe CS. et al. Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves' disease. J Immunol 2013; 190: 5373-5381
    CrossrefPubMedGoogle Scholar
  • 3 Seib CD, Chen J, Iagaru A. Shifting trends and informed decision-making in the management of Graves’ disease. Thyroid 2020; 3: 351-354
    CrossrefPubMedGoogle Scholar
  • 4 Gibb FW, Zammitt NN, Beckett GJ. et al. Predictors of treatment failure, incipient hypothyroidism, and weight gain following radioiodine therapy for Graves' thyrotoxicosis. J Endocrinol Invest 2013; 36: 764-769
    PubMedGoogle Scholar
  • 5 Allahabadia A, Daykin J, Holder RL. et al. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038-1042
    PubMedGoogle Scholar
  • 6 Sabri O, Zimny M, Schulz G. et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84: 1229-1233
    CrossrefPubMedGoogle Scholar
  • 7 Moura-Neto A, Mosci C, Santos AO. et al. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease. Clin Nucl Med 2012; 37: 550-554
    CrossrefPubMedGoogle Scholar
  • 8 Murakami Y, Takamatsu J, Sakane S. et al. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 1996; 81: 3257-3260
    PubMedGoogle Scholar
  • 9 Walter MA, Christ-Crain M, Eckard B. et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 2004; 34: 365-370
    CrossrefPubMedGoogle Scholar
  • 10 Zantut-Wittmann DE, Ramos CD, Santos AO. et al. High pre-therapy (99mTc) pertechnetate thyroid uptake, thyroid size, and thyrostatic drugs: predictive factors of failure in (131I) iodide therapy in Graves' disease. Nucl Med Commun 2005; 26: 957-963
    CrossrefPubMedGoogle Scholar
  • 11 Boelaert K, Syed AA, Manji N. et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf) 2009; 70: 129-138
    CrossrefPubMedGoogle Scholar
  • 12 Liu M, Jing D, Hu J. et al. Predictive factors of outcomes in personalized radioactive iodine (131I) treatment for Graves' disease. Am J Med Sci 2014; 348: 288-293
    CrossrefPubMedGoogle Scholar
  • 13 Ross DS, Burch HB, Cooper DS. et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. J Thyroid 2016; 26: 1343-1421
    CrossrefPubMedGoogle Scholar
  • 14 Chen DY, Schneider PF, Zhang XS. et al. Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded endpoint study. J Thyroid 2011; 21: 647-654
    CrossrefPubMedGoogle Scholar
  • 15 Sundaresh V, Brito JP, Wang Z. et al. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98: 3671-3677
    CrossrefPubMedGoogle Scholar
  • 16 Rooij A, Vandenbroucke JP, Smit JW. et al. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 2009; 161: 771-777
    CrossrefPubMedGoogle Scholar
  • 17 Bojarska-Szmygin A, Janicki K, Pietura R. et al Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease. J Ann Univ Mariae Curie Sklodowska Med 2003; 58: 248-253
    PubMedGoogle Scholar
  • 18 Fangdu Li, Jimin Yuan, Zhongjia Wei. et al. Changes of apoptosis molecules in serum of patients with Graves' disease treated with 131I and their correlation. J Marker Immunoassay Clin 2005; 208: 208-210
    PubMedGoogle Scholar
  • 19 Jones BM, Kwok CC, Kung AW. Effect of radioactive iodine therapy on cytokine production in Gravesʼ disease: transient increases in interleukin-4 IL-4, IL-6, IL-10, and tumor necrosis factor-alpha, with longer term increases in interferon-gamma production. J Clin Endocrinol Metab 1999; 84: 4106-4110
    PubMedGoogle Scholar
  • 20 Panganiban RA, Mungunsukh O, Day RM. X-irradiation induces ER stress, apoptosis, and senescence in pulmonary artery endothelial cells. Int J Radiat Biol 2013; 89: 656-667
    CrossrefPubMedGoogle Scholar
  • 21 Wen G, Ringseis R, Eder K. Endoplasmic reticulum stress inhibits expression of genes involved in thyroid hormone synthesis and their key transcriptional regulators in FRTL-5 thyrocytes. Plos One 2017; 12: 61-78
    PubMedGoogle Scholar